NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News, & Analysis

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group announced that its board has authorized a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its stock is undervalued.

Cellular Biomedicine Group Inc (NASDAQ:CBMG) announced its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.04. The biotechnology company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 44.62% and a negative net margin of 13,988.39%. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Cellular Biomedicine Group.

2 equities research analysts have issued 12 month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $38.00 to $38.00. On average, they expect Cellular Biomedicine Group's stock price to reach $38.00 in the next year. This suggests a possible upside of 101.0% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

News articles about CBMG stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellular Biomedicine Group earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the immediate future.

Some companies that are related to Cellular Biomedicine Group include Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Novavax (NVAX), Acorda Therapeutics (ACOR), Vericel (VCEL) and Coherus Biosciences (CHRS).

Cellular Biomedicine Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.02%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $18.91.

Cellular Biomedicine Group has a market capitalization of $369.95 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]